LON:OXP - (OXP.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New (OXP.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
This price target is based on 0 analysts offering 12 month price targets for (OXP.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
N/A
The current consensus among 0 investment analysts is to n/a stock in (OXP.L). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
5/9/2017N+1 SingerReiterated Ratingcorporate
i
11/9/2016N+1 SingerReiterated RatingCorporate
i
7/21/2016Beaufort SecuritiesDowngradeHold
i
(Data available from 4/14/2016 forward)
(OXP.L) logo
Oxford Pharmascience Group plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in re-developing medicines. The Company primarily engages in research and development activities based around its core technology platforms and focuses on commercializing the related products to pharmaceutical organizations. It operates through one segment, being the development and commercialization of drug products from proprietary technology platforms. The Company operates in three main geographic areas, such as the United Kingdom, Middle East and Brazil. The Company is primarily focused on commercialization efforts for its compounds OXPzero Ibuprofen and OXPzero Naproxen and in regulatory, technical and clinical activities in support of these assets. It is focused on establishing a number of commercial partnerships that demonstrate the commercial feasibility of the technology. The Company's subsidiaries include Oxford Pharmascience Limited and Oxford Nutra Limited.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

16,260 shs

Average Volume

803,502 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (OXP.L)?

The following equities research analysts have issued reports on (OXP.L) in the last year:
View the latest analyst ratings for OXP.

What is the current price target for (OXP.L)?

0 Wall Street analysts have set twelve-month price targets for (OXP.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for (OXP.L) in the next year.
View the latest price targets for OXP.

What is the current consensus analyst rating for (OXP.L)?

(OXP.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OXP.

How do I contact (OXP.L)'s investor relations team?

(OXP.L)'s physical mailing address is 2 Royal College Street, LONDON, NW1 0NH, United Kingdom. The company's listed phone number is +44-20-75545875. The official website for (OXP.L) is www.oxfordpharmascience.com.